Back to search

Article

Propofol overcome Tamoxifen resistance in breast cancer by modulating tumorogenesis, immune response and metabolism

2024-04-20

Abstract excerpt

Although 70% of estrogen receptor (ER)-positive breast cancer patients benefit from Tamoxifen therapy, the developing resistance to Tamoxifen leads to high rates of metastasis and poor prognosis. Propofol, a commonly used anesthetic, has been shown to inhibit the occurrence and development of breast cancer. However, its role in anti-endocrine resistance in ER-positive breast cancer remains unclear. In this study,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9db3f5fb-a5c7-5117-9964-9466f6f56f05
DOI
10.1101/2024.04.15.589641
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Propofol overcome Tamoxifen resistance in breast cancer by modulating tumorogenesis, immune response and metabolismDOI 10.1101/2024.04.15.589641
Select a neighboring publication to make it the new centre.